Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study
Abstract Multiple myeloma (MM) is a complex hematological malignancy of clonal plasma cells driven by alterations to the chromosomal material leading to uncontrolled proliferation in the bone marrow. Ethnic and racial disparities persist in the prevalence, diagnosis, management, and outcomes of MM....
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2024-12-01
|
| Series: | Blood Cancer Journal |
| Online Access: | https://doi.org/10.1038/s41408-024-01206-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850100672833257472 |
|---|---|
| author | Majid Jaberi-Douraki Xuan Xu Danai Dima Sikander Ailawadhi Faiz Anwer Sandra Mazzoni Jason Valent Muhammad Hamza Habib Jim E. Riviere Shahzad Raza |
| author_facet | Majid Jaberi-Douraki Xuan Xu Danai Dima Sikander Ailawadhi Faiz Anwer Sandra Mazzoni Jason Valent Muhammad Hamza Habib Jim E. Riviere Shahzad Raza |
| author_sort | Majid Jaberi-Douraki |
| collection | DOAJ |
| description | Abstract Multiple myeloma (MM) is a complex hematological malignancy of clonal plasma cells driven by alterations to the chromosomal material leading to uncontrolled proliferation in the bone marrow. Ethnic and racial disparities persist in the prevalence, diagnosis, management, and outcomes of MM. These disparities are multifaceted and intersect with various factors, including demographics, geography, socioeconomic status, genetics, and access to healthcare. This study utilized the openFDA human drug adverse events (AEs) to analyze global data pertaining to MM patients and patterns of treatment-related AEs. We identified ten most frequently used drugs and drug regimens in six distinct regions, including North America (NA), Europe (EU), Asia (AS), Africa (AF), Oceania (OC), and Latin America & the Caribbean (LA). AE patterns were evaluated using the reporting odds ratio combined with a 95% confidence interval. AE reports were more prevalent in men than in women across all regions. Cardiotoxicities were more likely observed in AS and EU, while secondary neoplasms were more frequently reported in the EU. Nephropathies were prominent in OC, AF (in males), and AS (in females), while vascular toxicity, including embolism and thrombosis, was more common in NA (in males). A notable improvement in survival, particularly in AS, EU, and NA, with a significant decline in death rates was observed. Hospitalization rates displayed less variation in AS and EU but exhibited more pronounced fluctuations in AF, LA, and OC. In conclusion, this comprehensive analysis offers valuable insights into the demographic, geographic, and AE patterns of MM patients across the globe. |
| format | Article |
| id | doaj-art-405474d19bc14e7bbe003f7abb5de791 |
| institution | DOAJ |
| issn | 2044-5385 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Blood Cancer Journal |
| spelling | doaj-art-405474d19bc14e7bbe003f7abb5de7912025-08-20T02:40:14ZengNature Publishing GroupBlood Cancer Journal2044-53852024-12-0114111010.1038/s41408-024-01206-4Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance studyMajid Jaberi-Douraki0Xuan Xu1Danai Dima2Sikander Ailawadhi3Faiz Anwer4Sandra Mazzoni5Jason Valent6Muhammad Hamza Habib7Jim E. Riviere8Shahzad Raza91DATA Consortium, Kansas State University Olathe1DATA Consortium, Kansas State University OlatheFred Hutchinson Cancer Center, University of WashingtonDepartment of Hematology, Mayo ClinicDepartment of Hematology & Oncology, Taussig Cancer Institute, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University School of MedicineDepartment of Hematology & Oncology, Taussig Cancer Institute, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University School of MedicineDepartment of Hematology & Oncology, Taussig Cancer Institute, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University School of MedicineDepartment of Palliative Care, Rutgers Robert Wood Johnson School of Medicine1DATA Consortium, Kansas State University OlatheDepartment of Hematology & Oncology, Taussig Cancer Institute, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University School of MedicineAbstract Multiple myeloma (MM) is a complex hematological malignancy of clonal plasma cells driven by alterations to the chromosomal material leading to uncontrolled proliferation in the bone marrow. Ethnic and racial disparities persist in the prevalence, diagnosis, management, and outcomes of MM. These disparities are multifaceted and intersect with various factors, including demographics, geography, socioeconomic status, genetics, and access to healthcare. This study utilized the openFDA human drug adverse events (AEs) to analyze global data pertaining to MM patients and patterns of treatment-related AEs. We identified ten most frequently used drugs and drug regimens in six distinct regions, including North America (NA), Europe (EU), Asia (AS), Africa (AF), Oceania (OC), and Latin America & the Caribbean (LA). AE patterns were evaluated using the reporting odds ratio combined with a 95% confidence interval. AE reports were more prevalent in men than in women across all regions. Cardiotoxicities were more likely observed in AS and EU, while secondary neoplasms were more frequently reported in the EU. Nephropathies were prominent in OC, AF (in males), and AS (in females), while vascular toxicity, including embolism and thrombosis, was more common in NA (in males). A notable improvement in survival, particularly in AS, EU, and NA, with a significant decline in death rates was observed. Hospitalization rates displayed less variation in AS and EU but exhibited more pronounced fluctuations in AF, LA, and OC. In conclusion, this comprehensive analysis offers valuable insights into the demographic, geographic, and AE patterns of MM patients across the globe.https://doi.org/10.1038/s41408-024-01206-4 |
| spellingShingle | Majid Jaberi-Douraki Xuan Xu Danai Dima Sikander Ailawadhi Faiz Anwer Sandra Mazzoni Jason Valent Muhammad Hamza Habib Jim E. Riviere Shahzad Raza Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study Blood Cancer Journal |
| title | Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study |
| title_full | Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study |
| title_fullStr | Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study |
| title_full_unstemmed | Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study |
| title_short | Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study |
| title_sort | global disparities in drug related adverse events of patients with multiple myeloma a pharmacovigilance study |
| url | https://doi.org/10.1038/s41408-024-01206-4 |
| work_keys_str_mv | AT majidjaberidouraki globaldisparitiesindrugrelatedadverseeventsofpatientswithmultiplemyelomaapharmacovigilancestudy AT xuanxu globaldisparitiesindrugrelatedadverseeventsofpatientswithmultiplemyelomaapharmacovigilancestudy AT danaidima globaldisparitiesindrugrelatedadverseeventsofpatientswithmultiplemyelomaapharmacovigilancestudy AT sikanderailawadhi globaldisparitiesindrugrelatedadverseeventsofpatientswithmultiplemyelomaapharmacovigilancestudy AT faizanwer globaldisparitiesindrugrelatedadverseeventsofpatientswithmultiplemyelomaapharmacovigilancestudy AT sandramazzoni globaldisparitiesindrugrelatedadverseeventsofpatientswithmultiplemyelomaapharmacovigilancestudy AT jasonvalent globaldisparitiesindrugrelatedadverseeventsofpatientswithmultiplemyelomaapharmacovigilancestudy AT muhammadhamzahabib globaldisparitiesindrugrelatedadverseeventsofpatientswithmultiplemyelomaapharmacovigilancestudy AT jimeriviere globaldisparitiesindrugrelatedadverseeventsofpatientswithmultiplemyelomaapharmacovigilancestudy AT shahzadraza globaldisparitiesindrugrelatedadverseeventsofpatientswithmultiplemyelomaapharmacovigilancestudy |